Quarterly report · Q1
6960.TEDINET S100OV56
Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥132.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.6bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥4.2bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.4bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.3bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥2.8bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥191.7bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥195.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥182.0bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥41.9bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥45.6bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥149.8bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥149.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥137.5bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥64.0bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥64.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥188.54 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,072.38 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.31 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 78.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.8bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.8bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥817m |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥282m |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥583m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥7.4bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥7.4bn |
| jpcrp040300-q1r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥931m |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥2.3bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥2.6bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥2.6bn |
| jpcrp040300-q1r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥344m |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥5.0bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥5.0bn |
| jpcrp040300-q1r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥597m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥27.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥27.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥4.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 365
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding trade notes receivable discounted or transferred by endorsement (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |